Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 10,981

Document Document Title
WO/2017/056055A1
Benzimidazolo[1,2-a]benzimidazole carrying triazine groups, an organic electronic device, comprising said benzimidazolo[1,2-a]benzimidazole carrying triazine groups, an electron transport layer, an electron injection layer, or an emittin...  
WO/2017/057747A1
The objective of the present invention is to provide: a compound and a composition for forming an organic semiconductor film, each of which enables the formation of an organic semiconductor film having excellent heat resistance; an organ...  
WO/2017/050732A1
The invention provides novel compounds having the general formula (I), (I) wherein R1, R2, R9, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.  
WO/2017/049711A1
Disclosed are a quinoline derivative, and a pharmaceutical composition, a preparation method and a use thereof. The quinoline derivative of the present invention has a c-Met inhibitory activity and can be used for the treatment, relievin...  
WO/2017/045510A1
Provided are compounds shown in general formulae (I)-(IV) capable of being used as β-lactamase inhibitors, pharmaceutically acceptable salts thereof, esters thereof, and stereoisomers thereof, where R1, R2, M, and a ring A are as define...  
WO/2017/046675A1
The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined ...  
WO/2017/046606A1
This invention relates to antibacterial and antimycobacterial drug compounds of formula (I). It also relates to pharmaceutical formulations of antibacterial drug compounds of formula (I). It also relates to uses of the derivatives in tre...  
WO/2017/043175A1
Provided is a near-infrared absorbing curable composition which is capable of forming a cured film that has excellent infrared light shielding properties and visible light transparency, while exhibiting excellent heat resistance and ligh...  
WO/2017/042182A1
Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substi...  
WO/2017/042114A1
The present invention relates to compounds of formula (I); hetaryl is a five membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N; R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted b...  
WO/2017/043550A1
The purpose of the present invention is to provide a novel RET inhibitor and a prophylactic or therapeutic agent for diseases that can be prevented or treated with the assistance of a RET inhibition activity (e.g., malignant tumors), eac...  
WO/2017/040448A1
The invention relates generally to compounds that modulate the activity of TGFBETA R-1 and TGFBETA R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated a...  
WO/2017/037221A1
The invention relates to antibacterial compounds of formula (I) wherein M is one of the groups MA, MB and MC represented below wherein R1, MA, MB and MC are as defined in the specification; and to salts thereof.  
WO/2017/037639A1
The present invention relates to an improved process for the preparation of xylene linked cyclam compounds. More particularly the invention provides a process for preparation of high purity plerixafor which does not involve the use of ex...  
WO/2017/035366A1
This application relates to compounds of Formula I or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.  
WO/2017/030814A1
The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by ...  
WO/2017/031427A1
Compounds having activity as mTOR inhibitors are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, and A are as defined here...  
WO/2017/026516A1
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof or a solvate of these. The present invention provides a compound having Nrf2 activation ability.  
WO/2017/024015A1
4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by...  
WO/2017/020831A1
Provided is an organic light-emitting compound shown in a general formula (I) and use thereof in preparation of an organic light-emitting device. The provided organic light-emitting compound is capable of reducing a working voltage of th...  
WO/2017/021981A1
The present invention relates to a dosage form comprising an aqueous solution of a vinca alkaloid drug or its pharmaceutically acceptable salt in a flexible infusion container, and a light protective secondary packaging containing the fl...  
WO/2017/019429A1
Phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds of Formula I, formulations containing those compounds, and their use as mutant isocitrate dehydrogenase 1 enzyme inhibitors.  
WO/2017/018153A1
The present invention provides a compound represented by general formula (I) (wherein Ra0 represents a hydrogen atom, a hydroxy group, an alkyl group having 1 to 12 carbon atoms, or an alkenyl group having 3 to 12 carbon atoms; Ra1, Ra2,...  
WO/2017/015267A1
Compounds of the formulas I and XIII, which are useful as colony stimulating factor-1 receptor inhibitors ("CSF 1R inhibitors").  
WO/2017/010124A1
The present invention addresses the problem of providing an organic thin-film laminate with which it is possible to suppress function reduction even when an intermediate layer is formed using a wet method. The organic thin-film laminate ...  
WO/2017/009804A1
The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases a...  
WO/2017/005583A1
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising th...  
WO/2017/006968A1
The present invention provides: a method for producing a 7H-pyrrolo[2, 3-d]pyrimidine derivative that is useful as a janus kinase (JAK) inhibitor; an intermediate of the 7H-pyrrolo[2, 3-d]pyrimidine derivative; and a method for producing...  
WO/2017/000779A1
Provided is an organic compound as shown by formula (I), which is a high performance material obtained by coupling anthracene and a derivative of anthracene with phenanthroline via a naphthyl. Also provided are an electronic material wit...  
WO/2017/001660A1
The present invention relates to the following compounds, wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.  
WO/2017/004025A1
The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 do...  
WO/2017/004408A1
Disclosed are new small molecules having a 4-methylpyrrrolo[l,2-a]pyrimidine- 8-carboxamide core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the sma...  
WO/2016/209951A1
Macrocyclic benzodiazepine dimers having a structure represented by formula (I) where A and B are independently according to formulae (Ia) or (Ib) ]; and the other variables in formulae (I), (Ia), and (Ib) are as defined in the applicati...  
WO/2016/208595A1
The present invention pertains to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the signs set forth in the description), or a salt, a solvate or an N-oxide thereof, or a prodrug of tho...  
WO/2016/203404A1
The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.  
WO/2016/203401A1
The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.  
WO/2016/202800A1
New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositid...  
WO/2016/205113A1
A number of new classes of polymers with the potential for electrical conduction are introduced sharing a common theme, having metal atoms in direct contact with each other, bound in one and two-dimensional structures guided by steric, d...  
WO/2016/204135A1
The present invention relates to a compound, or a pharmacologically acceptable salt thereof, that has excellent hypoglycemic action. A compound represented by general formula (I) or a pharmacologically acceptable salt thereof. [In the fo...  
WO/2016/198869A1
The invention relates to pyrridinobenzodiazepines (PDDs) comprising three fused 6-7- 6–membered rings and to benzopyrridodiazecines (BPDs) comprising three fused 6-8- 6–membered rings and, in particular, to PDD or BPD dimers linked t...  
WO/2016/197584A1
The present invention relates to the field of preparation of natural plant extracts, and particularly relates to a method of extracting Azadirachtin from neem seeds. The method comprises: first adding peeled neem seeds and sodium rosinat...  
WO/2016/201219A1
The disclosure relates to compositions and methods for the treatment of fungal, bacterial, and parasitic infections and inhibition of fungal, bacterial, and parasitic growth. In particular, such compositions include dihydrofolate reducta...  
WO/2016/200339A1
A compound of formula I, wherein the compound of formula I has the structure: wherein R1 to R5, Y, L, Z and X1 to X7 have meanings given in the description, said compounds having utility in the treatment of hyperproliferative disease.  
WO/2016/197987A1
The present invention provides a heterocyclic compound serving as a Syk inhibitor and/or a Syk-HDAC dual inhibitor. Specifically, the present invention provides a compound represented by formula (I), wherein each group is defined by a de...  
WO/2016/192329A1
A benzo[g]phthalazine-containing aromatic heterocyclic compound as represented by formula (I), a preparation method for the compound, and an organic electroluminescent component comprising the compound. The compound as represented by for...  
WO/2016/192346A1
Provided is an aromatic heterocyclic derivative having a structure as represented by formula (I). Compared with the prior art, the aromatic heterocyclic derivative provided in the present invention is such that groups Q1, Q2, Ar1, Ar2, A...  
WO/2016/194831A1
The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.  
WO/2016/191524A1
The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compos...  
WO/2016/189304A1
The present invention relates to antibacterial drug compounds containing a polycyclic ring system incorporating a macrocyclic ring. The invention also relates to pharmaceutical formulations of antibacterial drug compounds. The invention ...  
WO/2016/184832A1
The present invention provides compounds of formula (I) wherein A, X, Y, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the comp...  

Matches 651 - 700 out of 10,981